Mindmed announces positive results from collaborators' placebo-controlled investigator-initiated trial published in peer-reviewed journal

- data from university hospital basel (uhb) study supports the clinical development of mindmed's proprietary mm-120 product candidate for generalized anxiety disorder ("gad") – - patient dosing in phase 2b trial ongoing for mm-120 in gad– - mindmed currently owns and retains all clinical data and manufacturing rights for mm-120 and intends to continue broadening its intellectual property portfolio - new york , sept. 8, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that the manuscript "lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness a randomized, double-blind, placebo-controlled phase ii study," has been published in the peer-reviewed scientific journal biological psychiatry.
MNMD Ratings Summary
MNMD Quant Ranking